Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways

Figure 1 Allyl isothiocyanate reduces body weight, ameliorates hepatic steatosis and attenuates liver injury in high fat diet-fed mice. A: Body weight evaluated weekly; B: Body weight at week 8; C: Representative liver sections stained with hematoxylin and eosin (H&E) (left panel) or oil red O (middle panel) and macroscopic pictures of livers (right panel). D: Liver weight; E: Intrahepatic triglyceride (TG) content. Liver function was evaluated by detecting serum levels of alanine aminotransferase (ALT) (F), aspartate aminotransferase (AST) (G), total cholesterol (H) and uric acid (I). Scale bar in panel represents 100 μm. Data are presented as the mean ± S.D. ^aP < 0.05, ^bP < 0.01 vs HFD(-) AITC(-), ^dP < 0.01 vs HFD(+) AITC(-). HFD: High fat diet; AITC: Allyl isothiocyanate; TG: Triglyceride; H&E: Hematoxylin and eosin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.